Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223779 · ClinicalTrials.gov registry record · Phase 1
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03223779: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03223779 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03223779, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer. The interventions involved in this study are: * Trifluridine (TAS-102) * Radiation Therapy
Interventions
- DRUG TAS-102
- RADIATION Photon SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2025-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223779
The ClinicalTrials.gov registry entry for NCT03223779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAS-102 is the first listed.
NCT03223779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03223779 about?
NCT03223779 is a clinical study titled "Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer". This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer. The interventions involved in this study are: * Trifluridine (TAS-102) * Radiation Therapy
What is the current status of trial NCT03223779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-10-13. Estimated completion is 2025-10-02.
What interventions are being tested in trial NCT03223779?
The interventions under investigation include: TAS-102 (DRUG), Photon SBRT (RADIATION).
Who is sponsoring clinical trial NCT03223779?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.